1. Exploit CT (plain scan), enhanced CT and fMRI based radiomic biomarkers, explore their correlation with the prognostic molecular markers of spinal GCTB(p53/vegf/rank/rankl…), and help accurate diagnosis of GCTB. 2. Exploring a new method of preoperative risk stratification for spinal GCTB, and establishing radiomic model combined with clinical features. Exploring the GCTB biological behavior prediction model and the prognosis prediction of GCTB.
This study intends to conduct a systematic review of patients with spinal GCTB who have undergone standardized imaging (CT or MRI) in our hospital since 2006 to obtain case samples, conduct standardized clinical and imaging data extraction and analysis, and fully integrate histopathology and clinical follow-up results. To preliminarily explore the value of postoperative imaging-based radiomics markers in the preoperative precise diagnosis of spinal GCTB, risk stratification and prediction of tumor biological behavior.
Study Type
OBSERVATIONAL
Enrollment
100
Immunohistochemical staining was performed using the following antibodies: anti-RANK antibody from Bioss Company (No.bs-2695R) and anti-RANKL antibody from Abcam (No.ab222215).
Peking University third hospital
Beijing, Please Select An Option Below, China
RANK/RANKL
Grade:low;high(Receptor Activator of Nuclear factor Kappa-Β/Ligand)
Time frame: 2020
VEGF
Grade:low;high(Vascular Endothelial Growth Factors)
Time frame: 2020
p53
Grade:low;high(Tumor Suppressor Protein)
Time frame: 2020
Recurrence
recurrence group/non-recurrence group
Time frame: 2020
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.